These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 28001095)
1. Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells. Tvedt TH; Nepstad I; Bruserud Ø Expert Opin Investig Drugs; 2017 Mar; 26(3):343-355. PubMed ID: 28001095 [TBL] [Abstract][Full Text] [Related]
2. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia. Luskin MR; DeAngelo DJ Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942 [TBL] [Abstract][Full Text] [Related]
3. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia. Kim M; Williams S Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051 [TBL] [Abstract][Full Text] [Related]
5. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive. Garcia JS; Percival ME Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055 [TBL] [Abstract][Full Text] [Related]
6. Midostaurin for the treatment of acute myeloid leukemia. Patnaik MM Future Oncol; 2017 Sep; 13(21):1853-1871. PubMed ID: 28610444 [TBL] [Abstract][Full Text] [Related]
7. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia. Stansfield LC; Pollyea DA Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600 [TBL] [Abstract][Full Text] [Related]
8. Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin. Arnán Sangerman M; Fernández Moreno A; García Quintana A; García-Vidal C; Olave Rubio MT; Del Mar Tormo Díaz M; Vendranas M; Rodriguez Macias G Expert Rev Hematol; 2022 Mar; 15(3):203-214. PubMed ID: 35332831 [TBL] [Abstract][Full Text] [Related]
9. Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis. Schlenk RF; Kayser S Recent Results Cancer Res; 2018; 212():199-214. PubMed ID: 30069632 [TBL] [Abstract][Full Text] [Related]
10. A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients. Cooper BW; Kindwall-Keller TL; Craig MD; Creger RJ; Hamadani M; Tse WW; Lazarus HM Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):428-432.e2. PubMed ID: 25776192 [TBL] [Abstract][Full Text] [Related]
11. Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. Weisberg E; Meng C; Case AE; Tiv HL; Gokhale PC; Buhrlage SJ; Yang J; Liu X; Wang J; Gray N; Adamia S; Sattler M; Stone R; Griffin JD J Cell Mol Med; 2020 Mar; 24(5):2968-2980. PubMed ID: 31967735 [TBL] [Abstract][Full Text] [Related]
12. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. Fischer T; Stone RM; Deangelo DJ; Galinsky I; Estey E; Lanza C; Fox E; Ehninger G; Feldman EJ; Schiller GJ; Klimek VM; Nimer SD; Gilliland DG; Dutreix C; Huntsman-Labed A; Virkus J; Giles FJ J Clin Oncol; 2010 Oct; 28(28):4339-45. PubMed ID: 20733134 [TBL] [Abstract][Full Text] [Related]
13. FLT3 inhibitors in acute myeloid leukemia: Current and future. Thomas CM; Campbell P J Oncol Pharm Pract; 2019 Jan; 25(1):163-171. PubMed ID: 30270754 [TBL] [Abstract][Full Text] [Related]
14. MDM2- and FLT3-inhibitors in the treatment of Seipel K; Marques MAT; Sidler C; Mueller BU; Pabst T Haematologica; 2018 Nov; 103(11):1862-1872. PubMed ID: 29976747 [TBL] [Abstract][Full Text] [Related]
15. Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3. Lu H; Weng XQ; Sheng Y; Wu J; Xi HM; Cai X BMC Cancer; 2022 Jul; 22(1):749. PubMed ID: 35810308 [TBL] [Abstract][Full Text] [Related]
16. Isavuconazole therapy in an FLT3 mutated acute myeloid leukemia patient receiving midostaurin: A case report. Tollkuci E J Oncol Pharm Pract; 2019 Jun; 25(4):987-989. PubMed ID: 29558838 [TBL] [Abstract][Full Text] [Related]
17. Midostaurin in FLT3-mutated acute myeloid leukaemia. Das M Lancet Oncol; 2017 Aug; 18(8):e439. PubMed ID: 28669736 [No Abstract] [Full Text] [Related]
18. A Phase II Study of Midostaurin and 5-Azacitidine for Untreated Elderly and Unfit Patients With FLT3 Wild-type Acute Myelogenous Leukemia. Tomlinson BK; Gallogly MM; Kane DM; Metheny L; Lazarus HM; William BM; Craig MD; Levis MJ; Cooper BW Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):226-233.e1. PubMed ID: 32085993 [TBL] [Abstract][Full Text] [Related]
19. The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia. Marconi G; Giannini MB; Bagnato G; Simonetti G; Cerchione C; Mosquera Orgueira A; Musuraca G; Martinelli G Expert Opin Drug Saf; 2021 Jul; 20(7):791-799. PubMed ID: 33853481 [TBL] [Abstract][Full Text] [Related]
20. Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis. Sly N; Gaspar K Am J Health Syst Pharm; 2019 Feb; 76(5):268-274. PubMed ID: 30753289 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]